Advanced Urothelial Carcinoma
Advertisement
In those who did not undergo EV treatment, NECTIN4 amplifications were not connected with outcomes.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
While ICIs have become a novel treatment option for mUC, attrition rates may affect their impact on long-term survival.
Dr. Sonpavde provides an overview of the potential of nivo/gem-cis for patients with mUC who are ineligible for EV/pembro.
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Patients who received EV over chemotherapy maintained their HRQOL levels and experienced delayed HRQOL deterioration.
Patients with mutations in the UGT1A1 gene can experience adverse events when treated with irinotecan-based therapies.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
The impact of squamous and other histologies on outcomes with EV are dissected.
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.